Log In
Tuesday 20th March 2018

Alizyme on brink of deal

17th April 2007

Cambridge-based pharmaceutical company Alizyme is trying to secure licensing deals for four drugs in the latter stages of development. 

If the deal goes ahead it could change the financial fortunes of the company which saw its shares fall steadily last year.  However, following a change in executive management shares have begun to recover but what will really instill trust in new investors is if the company can secure a licensing deal.  New CEO Tim McCarthy said he understood investors’ frustrations but added that 2007 looked like it was going to be a good year for the company.




Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018